FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

  • End date
    Jul 24, 2025
  • participants needed
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 24 January 2021
treatment regimen
neutrophil count
adjuvant therapy
metastatic pancreatic cancer
pancreatic neoplasm


Pancreatic adenocarcinoma (PAC) incidence increases regularly in Western countries and it is expected to become the second leading cause of cancer-related mortality in 2020. The prognosis of this disease remains very poor with an overall 5-year survival rate less than 5%.

The FOLFIRINOX regimen (5-fluorouracil [5-FU], folinic acid, irinotecan, and oxaliplatin) and the combination of nab-paclitaxel with gemcitabine demonstrated to be more effective than gemcitabine alone, and are both validated as standard first-line treatment options for metastatic PAC. However, the use of FOLFIRINOX is limited to patients with ECOG performance status (PS) 0-1 and aged less than 75 years. Nab-paclitaxel is currently not reimbursed in France.


This trial is an open label, multicenter, randomized phase III trial comparing gemcitabine vs FOLFOX in patients with metastatic pancreatic adenocarcinoma and non-fit for FOLFIRINOX. Adults fulfilling inclusion criteria and non-inclusion criteria will be randomized between a FOLFOX arm and a gemcitabine arm. The primary endpoint is the overall survival (OS) at 24 months. The secondary objectives are : objective response rate and disease control rate (RECIST v1.1, in case of evaluable lesion), duration of response, duration of disease control, progression free survival (PFS), the evolution of biomarkers Ca 19-9 and CEA under treatment, the toxicities according to International Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, the safety of both arms, the quality of life, the dose intensity (DI) of each protocol, the Quality-Adjusted Survival, and the rate and type of second-line / third-line regimens chemotherapy. With an expected median survival time in the control group of 5 months, an accrual period of 3 years and a minimum follow-up period of 2 years, a total of 199 patients per group are required to detect a hazard ratio of 0.75 based on a 5% two-sided type I error rate and a power of 80%, leading to a total number of 400 patients to include.

Condition Pancreatic Adenocarcinoma
Treatment Gemcitabine, FOLFOX
Clinical Study IdentifierNCT04167007
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Signed and dated informed consent, and willing and able to comply with protocol requirements
Histologically or cytologically proven adenocarcinoma of the pancreas
In absence of histologically or cytologically proven adenocarcinoma, a cluster of clinical, biological and radiological arguments consistent with the diagnosis: among these, a hypodense pancreatic tumor at CT and a Ca 19-9 greater than 500 UI/ml are essential prerequisites
Metastatic disease confirmed (stage IV)
No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months)
Age 18 years
Patient non-fit for FOLFIRINOX
For patients with ECOG performance status (PS ) 2, an albuminemia level >25 g/l is required
Haematological status: neutrophils (ANC) >2x109/L; platelets >100x109/L; haemoglobin 9g/dL
Adequate renal function: serum creatinine level <150M, and estimated creatinine clearance >30ml/min
Adequate liver function: AST (SGOT) and ALT (SGPT) 2.5xULN (5xULN in case of liver metastases)
Total bilirubin 3 x ULN
QT / QTc interval at baseline ECG (performed within 1 month before randomization) < than 450 msec for men and < than 470 msec for women
Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization
Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test ( HCG) within 7 days prior to starting protocol treatment. Breastfeeding is not allowed
Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment
Affiliation to a French social security system (recipient or assign)

Exclusion Criteria

History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy)
Local or locally advanced disease (stage I to III)
Patient uses warfarin
Patient receiving concomitant radiotherapy
Electrolytic report uncontrolled: hypercalcemia and/or hypokalemia and/or hypomagnesemia
Pre-existing permanent neuropathy (NCI grade 2 )
Poor nutritional status
Known dihydropyrimidine dehydrogenase (DPD) total or partial deficiency (DPD activity dosage at inclusion visit)
Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy)
Treatment with any other investigational medicinal product within 28 days prior to study entry
Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months)
Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C
Known uncontrolled bacterial infection
History or active interstitial lung disease (ILD)
Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years
Patients with known allergy to active substance or any excipient of study drugs
Allergy to iodinated contrast product
Concomitant administration of live, attenuated virus vaccine and concomitant administration of prophylactic phenytoin
Patients under legal protection or unable to consent
Participation in another interventional research
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note